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22The advent of high-throughput technologies has provided exceptional assistance for
lung scientists to discover novel genetic variants underlying the development and
progression of complex lung diseases. However, the discovered variants thus far
do not explain much of the estimated heritability of complex lung diseases. Here,
we review the literature of successfully used genome-wide association studies
(GWASs) and identified the polymorphisms that reproducibly underpin the suscepti-
bility to various noncancerous complex lung diseases or affect therapeutic
responses. We also discuss the inherent limitations of GWAS approaches and how
the use of next-generation sequencing technologies has furthered our understand-
ing about the genetic determinants of these diseases. Next, we describe the contri-
bution of the metagenomics to understand the interactions of the airways
microbiomewith lungdiseases.We then highlight the urgent need for new integrative
genomics-phenomics methods to more effectively interrogate and understandmul-
tiple downstream ‘‘omics’’ (eg, chromatin modification patterns). Finally, we address
the scarcity of genetic studies addressing under-represented populations such as
African Americans and Hispanics. (Translational Research 2016;168:22–39)Abbreviations: DNAseq ¼ DNA sequencing; GWAS ¼ genome-wide association study; NGS ¼
next-generation sequencingINTRODUCTIONH igh-throughput technologies have revolution-ized our understanding of the molecular mech-anisms underlying the development and
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.04.016progression of complex lung diseases. Importantly,
genome-wide association studies (GWASs) have played
a critical role as an advanced high-density genotyping
approach that allows for characterizing the contribution
of single-nucleotide polymorphisms (SNPs) scattered
across the genome to the genetic susceptibility of indi-
viduals. Specifically, GWAS benefits from the variety
of array platform technologies, by them the genotyping
of numerous common variants is possible. Until the
advent of GWAS in 2007, the genetic research of com-
plex inheritance was labor-intensive and biased,
focusing on identifying genetic variants based on prior
knowledge. GWAS offered a substantial higher rate of
discovery and was not limited by the need for an a priori
hypothesis or prior knowledge. However, the limited
number of probes in GWAS platforms (eg, 1 million
probes) compared with more than 79,000,000 variant
sites thus far identified by phase 3 release of 1000 Ge-
nomes Project (June 24, 2014) indicates a remaining
bias. Importantly, the rapidly reducing cost of next-
generation DNA sequencing (DNAseq) paves the way
Translational Research
Volume 168 Pouladi et al 23for a paradigm shift in discovery: personal polymor-
phisms inaccessible by biased methods.
Previous reviews in lung diseases focused primarily
on GWAS publications including descriptions of
disease-SNP associations observed in only 1 dataset.
The present study focused on replicated GWAS discov-
eries and new discoveries in whole genome sequencing
of patients with a variety of lung diseases. We summa-
rize the contribution of GWASs in identifying polymor-
phisms that confer risk to the development of specific
pulmonary disorders and the ones that may influence pa-
tient responses to therapy. In addition, we have included
a summary of next-generation sequencing (NGS) DNA-
seq findings benefiting from various NGS technologies.
The advent of NGS has made unbiased sequencing of
DNA faster and cheaper than that of Sanger sequencing
method. We did not include the lung cancer polymor-
phisms, as the number of discoveries in that specialty
would require an entire different review. Finally, we
reflect on the potential considerations and avenues for
future studies that would aim to catalog the genetic de-
terminants of complex lung diseases.
METHODS
We used NHGRI GWAS catalog1 to find the GWAS
publications that are related to various primary
noncancerous lung diseases; we found 81 curated pub-
lications. Among them, we focused on publications
with results of discovery cohorts that have been sepa-
rately and significantly replicated in their replication
cohorts. The tables comprise an exhaustive listing of
reproducible variants reported in the studied article.
The authors might have mapped a certain polymor-
phism onto more than 1 gene. Therefore, the number
of assigned genes might exceed the number of poly-
morphisms in several studies. We also used query
terms of the various pulmonary diseases plus terms
related to next-generation, whole exome, or whole
genome sequencing in PubMed to find the publications
where NGS have been used. We used the original arti-
cles and the GeneCards (http://www.genecards.org/) to
annotate the functions of the genes.
RESULTS
GWAS and complex pulmonary diseases. We divided
the studies reviewed into GWAS and NGS categories
with GWASs subdivided into 3 sections: obstructive pul-
monary diseases (asthma and chronic obstructive pulmo-
nary diseases [COPD]), restrictive pulmonary diseases,
and miscellaneous lung diseases. We also provide a sys-
tems biology interpretation of discovered variants. The
National Human Genome Research Institute (NHGRI)
catalog of reproducible published GWAS reports 207lung disease–associated SNPs from 32 publications. Of
these, 134 SNP-disease associations were reproducible
in independent cohorts. However, we identified that
only 61% of these SNPs were reported by the NHGRI
with the correct identifier as originally published in the
references. We also identified 13 reproducible lung
disease SNPs in these NHGRI-reported publications
that were missing in the NHGRI catalog. Here, we
review the entirety of these and provide the rectified
results in tables.
Obstructive pulmonary diseases. Asthma. Asthma is a
common chronic inflammatory disorder of the airways,
characterized by episodic and reversible airflowobstruc-
tion, airway hyper-responsiveness, and underlying
inflammation.2 In the United States, children, women,
racial and ethnic minorities, residents of inner cities,
and economically disadvantaged populations have a
disproportionately higher burden of asthma morbidity
and mortality when compared with the general popula-
tion.3-5 Among children younger than 18 years, asthma
is the third major cause of the hospital admissions.6 Of
note, the pattern of its prevalence is significantly
different with respect to various ages, countries with
different economic infrastructure, and degree of
severity.6 Duffy et al estimated that asthma heritability
is about 60%,7 highlighting the underlying role of
genetic determinants in asthma development.
Asthma susceptibility. Asthma genetic variants have
been the most studied among pulmonary diseases.
Moffatt et al8 conducted the first asthma GWAS and
uncovered the association of variants of ORMDL3,
which downregulates the sphingolipid synthesis, with
childhood-onset asthma (Table I). Himes et al subse-
quently performed a GWAS across asthma patients
of various ethnicities24 and discovered novel PDE4D
polymorphism in combined populations of Hispanics
and European descent but not in African American indi-
viduals (Table I). The authors also corroborated the
association of the ORMDL3 variants with asthma.
DeWan et al in a GWAS found evidence in favor of
the association of variants of PDE11A gene with child-
hood allergic asthma.25 Interestingly, both PDE11A
and PDE4D genes belong to the phosphodiesterase su-
perfamily of genes, implying the potential underlying
role of this superfamily in the development of asthma.25
In a seminal GWAS comprising about 30,000 cases
and controls, Moffatt et al discovered novel predispos-
ing asthma susceptibility variants (Table I).21 The list
contains interesting genes involved in T-cell responses
such as IL2RB and HLA-DQ. Interestingly, the authors
found that later-onset asthma is more influenced by ma-
jor histocompabibility complex (MHC) region (HLA-
DQ rs9273349) in contrast to childhood-onset asthma,
Table I. Asthma susceptibility polymorphisms
Study
Sub phenotype Ancestry Control 1 case
(replicates
included) Genes Variants ReferenceSusceptibility Progression European AFAM Hispanic Asian Other
GWAS and admixture
mapping identify different
asthma-associated loci in
Latinos: the Genes-
environments &
Admixture in Latino
Americans study
U U 7761 IKZF3, MUC21,
MUC22,
PBMUCL2
rs907092, 6p21 9
Genome-wide association
analysis identifies 11 risk
variants associated with
the asthma with hay fever
phenotype
U U 24,109 ZBTB10,
CLEC16A
rs7009110, rs62026376 10
A GWAS identifies CDHR3
as a susceptibility locus
for early childhood
asthma with severe
exacerbations
U U U U 24,913 CDHR3,
GSDMB, IL33,
RAD50,
IL1RL1
rs6967330, rs2305480,
rs928413,
rs6871536,
rs1558641
11
HLA-DQ strikes again:
GWAS further confirms
HLA-DQ in the diagnosis
of asthma among adults
U U U 15,054 HLA-DQA1 rs9272346 12
GWASs of asthma indicate
opposite
immunopathogenesis
direction from
autoimmune diseases
U U 37,015 IL1RL2, IL1R1,
TNIP1
rs3755285,
rs12619383,
rs1422673
13
GWAS to identify genetic
determinants of severe
asthma
U U U 5855 ORMDL3,
IL18R1, IL1R1
rs4794820, rs3771166,
rs9807989,
rs13035227
14
GWAS identifies PERLD1 as
asthma candidate gene
U U 2025 PERLD1 rs2941504 15
Identification of IL6R and
chromosome 11q13.5 as
risk loci for asthma
U U 57,800 IL6R, LRRC32 rs4129267, rs7130588 16
GWAS identifies 3 new
susceptibility loci for adult
asthma in the Japanese
population
U U 35,083 LOC729675,
TSLP,
WDR36,
NOTCH4,
LOC338591,
IKZF4
rs7686660, rs1837253,
rs404860,
rs10508372,
rs1701704
17
Meta-analysis of GWASs of
asthma in ethnically
diverse North American
populations
U U U U U 12,561 PYHIN1, IL1RL1,
TSLP, IL33,
GSDMB
rs1101999, rs3771180,
rs1837253,
rs2381416,
rs11078927
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GWAS identifies HLA-DP as
a susceptibility gene for
pediatric asthma in Asian
populations
U U 6420 HLA-DPA1,
SLC30A8
rs987870, rs3019885 19
Association between
ORMDL3, IL1RL1, and a
deletion on chromosome
17q21 with asthma risk in
Australia
U U 3436 IL1RL1,
ORMDL3
rs10197862, rs6503525 20
PDE11A associations with
asthma: results of a
genome-wide
association scan
U U U U 607 PDE11A rs11684634 25
A large-scale, consortium-
based GWAS of asthma
U U 30,478 IL18R1, HLA-DQ,
IL33, SMAD3,
GSDMB,
GSDMA,
IL2RB, HLA-
DRB1,
FCER1A, IL13,
STAT6, IL4-R/
IL21R
rs3771166, rs9273349,
rs1342326,
rs744910,
rs2305480,
rs3894194,
rs2284033,
rs9271300,
rs2252226, rs20541,
rs167769, rs1859308
21
Variants of DENND1B
associated with asthma in
children
U U U U 8956 DENND1B,
CRB1
rs2786098, rs1775456 22
A pooling-based genome-
wide analysis identifies
new potential candidate
genes for atopy in the
European Community
Respiratory Health
Survey
U U 876 SGK493 rs4952590 23
Genome-wide association
analysis identifies PDE4D
as an asthma-
susceptibility gene
U U U U 25,360 PDE4D rs1588265, rs1544791 24
Genetic variants regulating
ORMDL3 expression
contribute to the risk of
childhood asthma
U U 4557 ORMDL3 rs7216389 8
Abbreviations:U, yes; AFAM, African American; GWAS, genome-wide association study.
The entries of the table have been ordered based on the dates in which the studies were published from the bottom to the top.
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26 Pouladi et al February 2016which is primarily dominated by 17q region (GSDMA/
B) their findings failed to corroborate the role of genetic
determinants of lung function in predisposing the indi-
viduals to asthma. Afterward, Torgerson et al18 conduct-
ed a large meta-analysis in 2011. Their work included
admixed populations of African Americans, African
Caribbeans, and Hispanics. They revealed for the first
time an association of 4 previously known loci, namely
(i) 17q, (ii) Thymic stromal lymphopoietin (TSLP) that
enhances the T helper type 2 cell responses, (iii) Inter-
leukin 1 Receptor-Like 1 (IL1RL1), and (iv) Interleukin
33 (IL33) in 3 distinctive ethnicities. Additionally, they
discovered the association of novel variants of the PY-
HIN1 gene in African American asthmatic patients
(Table I). The pyrin domain of PYHIN1 is found in pro-
teins that are part of the apoptotic and inflammatory sig-
nals and respond to interferon.18
The contribution of GWAS approaches to uncover the
genetic determinants of asthma pathogenesis has not
been limited only to cases of European ancestry. Other
groups performed GWAS with focus on patients of
Asian descent.15,17,19 Two groups specifically
identified susceptibility polymorphisms of PERLD1
and HLA-DPA1 genes in Chinese and Japanese peoples,
respectively (Table I). PERLD1 particularly has some
effects on activation and proliferation of T cells.15 Hir-
ota et al17 also performed a GWAS in a cohort
comprising more than 7000 and 27,000 asthmatic and
control adult Japanese individuals, respectively. The
authors discovered 5 asthma susceptibility genomic
regions, namely 4q31, 5q22, 6p21, 10p14, and 12q13.
They mapped these 5 regions onto LOC729675,
TSLP-WDR36, NOTCH4, LOC338591, and IKZF4,
respectively (Table I). It is of interest that they repli-
cated the correlation of the polymorphism of TSLP
with asthma in an additional 499 non-Hispanic individ-
uals of European descent. Furthermore, they corrobo-
rated 3 previously known polymorphisms of
rs1063355 of HLA-DQ, rs11071559 of RORA, and
rs744910 of SMAD3. Recently, Galanter et al9 conduct-
ed a GWAS that included only Hispanics, who represent
an admixed population comprising varying combina-
tions of European, African, and Native American ances-
tries. Through an admixture-mapping technique, they
discovered a novel locus on 6p21 that includes mucin-
producing MUC21, MUC22, and PBMUCL2 genes
residing in the MHC region. They also corroborated
the previously known asthma region 17q21 in which
polymorphism of IKZF3 gene, which regulates the
development and proliferation of B lymphocyte, was
particularly the most significant one (Table I).
Most GWASs have primarily focused on asthma of
mild to moderate severity. However, Sleiman et al22
conducted a seminal GWAS in which the targetpopulation comprised children with persistent asthma
requiring daily inhaled glucocorticoid therapy. They
identified a novel predisposing asthma locus on chro-
mosome 1q31 that is mapped to the gene DENND1B,
a modulator of the type 1 helper T-cell cytokine
signaling pathway (Table I). They also replicated their
findings in a cohort comprising children of African
descent. Interestingly, they found that the allele of the
discovered variant in the population of African ancestry
is opposite to that of children of European descent.
Another group also focused on individuals with severe
asthma in their GWAS.14 They found the loci (2q12,
17q12–21) underlying the association with asthma
severity overlapped with the ones that had been already
discovered in previous GWASs (Table I). Bønnelykke
et al hypothesized that acute asthma exacerbation is
potentially a distinctive clinical phenotype. Therefore,
they identified asthma predisposing polymorphisms of
5 genes, namely CDHR3, IL1RL1, IL33, GSDMB,
and RAD50 (Table I).11 The CDHR3 gene that encodes
cadherin-related family member 3 was a novel finding,
whereas the remainder were previously known to be
associated with asthma. Of note, they showed that
rs6967330 variant of CDHR3 correlates with higher
risk of hospitalization in addition to severe exacerba-
tions. The findings from another GWAS with focus on
severe asthmatic patients are also interesting. Li et al
found the opposite effects of polymorphisms that corre-
late with asthma susceptibility and other autoimmune
diseases.13 For instance, they showed that asthma sus-
ceptibility variants of the IL13 and HLA-DRA genes
are protective against developing psoriasis and ulcera-
tive colitis, respectively.
Overall, the association of commonvariants of 7 genes
with asthma has been significantly reproduced in at least
2 well-replicated GWASs, namely ORMDL3/GSDMB
(17q12),8,11,14,18,20,21 TSLP (5q22),17,18 IL18R1/IL1R1/
IL1RL1 (2q12),11,13,14,18,20,21,26 and IL33 (9p24.1)
(Tables I and II).11,18,21
Endophenotypes as surrogates for asthma susceptibility.
Specific GWASs assessed the use of the endopheno-
types (eg, protein) as surrogates for asthma status. In
pioneering work, Ober et al28 conducted a GWAS to
identify variants correlating with YKL-40 levels. They
had previously shown that YKL-40 (a mediator of
airway inflammation) level in blood correlates with
the severity of asthma. Their effort uncovered that poly-
morphisms residing within gene CHI3L1, encoding
YKL-40, are significantly associated with quantitative
trait YKL-40 level, risk of asthma, and declined lung
function (Table II). Gudbjartsson et al26 also considered
the circulating eosinophil count as a quantitative trait,
because eosinophils are the most observed cell type in
the airways of asthmatic patients. They found several
Table II. Asthma susceptibility polymorphisms discovered through endophenotypes
Study Endophenotype
Ancestry Control 1 case
(replicates
included) Genes Variants ReferenceEuropean AFAM Hispanic Asian
GWAS of lung function
decline in adults with
and without asthma
Lung function decline U 16,136 DLEU7 rs9316500 27
A large-scale,
consortium-based
GWAS of asthma
IgE levels U 30,478 IL18R1, HLA-DQ, IL33,
SMAD3, GSDMB,
GSDMA, IL2RB, HLA-
DRB1, FCER1A, IL13,
STAT6, IL4-R/IL21R
rs3771166, rs9273349,
rs1342326, rs744910,
rs2305480, rs3894194,
rs2284033, rs9271300,
rs2252226, rs20541, rs167769,
rs1859308
21
Sequence variants
affecting eosinophil
numbers associate
with asthma and
myocardial infarction
Eosinophil counts U U 26,722 IL1RL1, IKZF2, GATA2, IL5,
SH2B3
rs1420101, rs12619285,
rs4143832, rs9494145,
rs3184504
26
Effect of variation in
CHI3L1 on serum
YKL-40 level, risk of
asthma, and lung
function
YKL-40 levels U 1772 CHI3L1 rs4950928 28
Abbreviations:U, yes; AFAM, African American; GWAS, genome-wide association study; IgE, immunoglobulin E.
The entries of the table have been ordered based on the dates in which the studies were published from the bottom to the top.
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28 Pouladi et al February 2016novel polymorphisms underlying asthma susceptibility
in patients of European descent (Table II). In a novel
effort, Imboden et al27 used the rate of the lung function
decline as an end point in their GWAS. Although they
did not find any significant polymorphism underlying
asthma risk, they discovered that a variant of the gene
DLEU7 correlates with FEV1 in nonasthmatic individ-
uals (Table II).
Increased circulating levels of immunoglobulin E
(IgE) are associated with the development of various in-
flammatory disorders such as asthma. Therefore, it is of
clinical interest to assess whether there is an overlap be-
tween the polymorphisms underlying circulating IgE
levels and those of asthma susceptibility. Moffatt
et al21 conducted a large meta-analysis on the individ-
uals of European descent (Table II). The authors identi-
fied a novel polymorphism of HLA-DRB1 in addition to
confirming previously identified variants influencing
IgE level. However, they noticed that the main genetic
determinants of asthma susceptibility and those of IgE
level were not dependent. Specifically, HLA-DRB1
and HLA-DQB1 that influence the increased IgE level
and asthma susceptibility, respectively, are in poor link-
age disequilibrium. Importantly, they also showed that
controlling for IgE level did not affect the predisposing
effect of HLA-DQB1 on asthma. The authors concluded
that increment of the IgE level is not probably a causal
factor in asthma development but a secondary phenom-
enon.
Asthma and response to therapeutic interventions.
GWAS approaches have been successfully used to un-
cover variants influencing the response to medications
in asthmatic patients. The prevalence of aspirin or
nonsteroidal anti-inflammatory drugs sensitivity, espe-
cially among patients with glucocorticoid-dependent
asthma can be as high as 10%–20%.29 Park et al29 con-
ducted a GWAS and uncovered the association of the
polymorphisms of the HLA-DPB1 gene with aspirin
intolerance in Korean people (Table III). Managing
the signs and symptoms of asthmatic patients is chal-
lenging because of the heterogeneity of response to ther-
apy among asthmatic patients.33 Among various
medications, inhaled glucocorticoids are the most
commonly prescribed therapy in clinical practice with
variable treatment response.33 Several studies have
used GWAS to identify polymorphisms underlying the
response to glucocorticoids. Tantisira et al32 showed
that rs37972 that maps to the gene GLCCI1 significantly
correlates with decreased responses to inhaled gluco-
corticoids. Another GWAS discovered a novel candi-
date gene T in asthmatic patients whose SNPs
influence the response to inhaled corticosteroids31
with a 2- to 3-fold difference in FEV1 response. Wu
et al30 showed that inhaled corticosteroids modify the
Translational Research
Volume 168 Pouladi et al 29response to b2-agonist through ZNF432 polymor-
phisms with patients carrying 2 copies of the mutant
allele in the presence of inhaled corticosteroids exhibit-
ing a greater b2-agonist response.
Chronic obstructive pulmonary diseases. The hallmark
of COPD is chronic inflammation of the airways,
emphysematous changes in the respiratory bronchioles,
and the acini leading to progressive obstruction of
airflow, which is largely irreversible. COPD is associ-
ated with several comorbidities such as heart failure
and diabetes.34 Importantly, theWorld Health Organiza-
tion estimates that COPD will be the third principal
cause of death by the year 2030.35 Although tobacco
smoking is a well-known risk factor for COPD and
its related pathogenesis,36,37 not all smokers contract
COPD, implying the underlying role of genetic
factors.38 GWAS has successfully contributed to the dis-
covery of the genetic polymorphisms (Table IV),
despite the fact that earlier studies suffer from the lack
of replicate cohorts and limited number of sample
size. For example, Siedlinski et al identified several
loci45 but failed to include a replication cohort. Cho
et al identified novel loci41 (FAM13A, RAB4B,
CHRNA3/5, IREB2, and HHIP) and recently focused
on moderate to severe or severe COPD cases.39 They
combined the data from COPDGene, ECLIPSE,
NETT/NAS, Norway GenKOLS, and International
COPD Genetics Network cohorts in a meta-analysis,
which also includes African American patients, to suc-
cessfully confirm the underpinning roles of previously
discovered genes CHRNA3 (a member of the nicotinic
acetylcholine receptor family), FAM13A (a GTPase
activator), and HHIP (a hedgehog family protein bind-
ing), and MMP12 (a member of matrix metalloprotei-
nase family) (Table IV). The authors also found
supporting evidence that the genes TGFB2, RIN3, and
the locus 19q13 play important roles in COPD suscepti-
bility. For example, they showed that rs4846480 is in
strong linkage disequilibrium with rs6684205, which
acts in pulmonary tissue as an expression quantitative
trait locus for TGFB2.39,46 Also, it is of interest that
candidate COPD susceptibility genes, such as HHIP
and FAM13A, overlap with genes that have a role in
the normal function of lung (Tables IV and VI ).55 It is
of interest that Manichaikul et al conducted a GWAS
across different ethnic groups in which they considered
percentage of emphysema as the outcome. They be-
came able to identify 2 polymorphisms rs7957346
near to SNRPF and rs10947233 within PPT2 genes
(Table IV).40 However, they replicated the discovered
SNPs only in patients of European descent.
Restrictive pulmonary disorders. Interstitial lung dis-
eases. Interstitial lung diseases (ILDs) are a heteroge-
neous group of pathologic conditions that manifestclinically and radiologically as diffuse parenchymal
lung disease. The pathologic findings of ILDs include
various stages and patterns of interstitial inflammation,
interstitial fibrosis, and alveolar filling. When a cause is
not clearly apparent, the term idiopathic interstitial
pneumonia (IIP) is used. Physiologically, ILDs gener-
ally manifest as a restrictive ventilatory defect and a
gas transfer defect.
Idiopathic pulmonary fibrosis. Idiopathic pulmonary
fibrosis (IPF) is the most common and the most severe
form of IIP.56,57 Despite the dismal prognosis of IPF, a
limited number of GWASs have been carried out thus
far to uncover the polymorphisms underlying its
course of development and progression. Our work
and work by others have shown common genetic
variants of telomerase reverse transcriptase (TERT)
(a regulator of telomerase activity), toll interacting
protein (TOLLIP) (an activator of MYD88-dependent
nuclear factor of kappa light polypeptide gene enhancer
in B-cells (NF-kB) to adjust the toll-like receptor
signaling and membrane trafficking), and MUC5B (an
important gel-forming mucin in mucus), to be strongly
associated with IPF susceptibility. Mushiroda et al49
in a GWAS on a group of Japanese patients with spo-
radic IPF found an association between the common
variants within the gene TERT and IPF (Table V). We
previously performed a GWAS to discover novel poly-
morphisms underlying IPF susceptibility47 (Table V)
and highlighted the importance of 11p15.5 in the devel-
opment and progression of IPF. We identified a novel
IPF susceptibility variant within TOLLIP and also
confirmed the association of previously known
MUC5B60 with IPF. Of note, we discovered that the
minor allele of the novel polymorphism of TOLLIP cor-
relates with the patients’ odds of mortality.47 Parallel to
our work, another group also confirmed the association
of IPF with MUC5B at 11p15, TERT at 5p15, and the
3q26 region near telomerase RNA component
(TERC).48 They also identified other novel polymor-
phisms both at significant and suggestive level of statis-
tical significance.
Granulomatous disorders. An important subgroup of
ILDs includes granulomatous disorders such as sar-
coidosis. The pathologic hallmark of sarcoidosis is the
presence of noncaseating epithelioid granulomas in
the absence of a known etiology. Sarcoidosis is a sys-
temic disorder affecting various organs with a wide
range of prognosis from self-limited disease to fatal
outcome.61 The studies focusing on monozygotic twins,
families, and various races have provided supporting ev-
idence in favor of putative genetic loci predisposing in-
dividuals to sarcoidosis.61 Previous GWASs have
successfully uncovered a limited number of non-HLA
common susceptibility loci (Table V). Among various
Table IV. COPD susceptibility polymorphisms
Study
Sub phenotype Ancestry
Control 1 case
(replicates
included) Genes Variants ReferenceSusceptibility Progression Endophenotype
Other/
description European AFAM Hispanic Asian Other
Risk loci for COPD: a
GWAS and meta-
analysis
U U U U 12,337 CHRNA3, FAM13A,
HHIP, MMP12,
RAB4B
rs12914385,
rs4416442,
rs13141641,
rs626750,
rs7937
39
Genome-wide study
of percent
emphysema on
computed
tomography in the
general
population. The
Multi-Ethnic Study
of Atherosclerosis
Lung/SNP Health
Association
Resource Study
U U Percentage of
emphysema
U U U U 7914 SNRPF, PPT2 rs7957346,
rs10947233
40
A GWAS of COPD
identifies a
susceptibility
locus on
chromosome
19q13
U U 8280 FAM13A,
RAB4B, EGLN2,
CYP2A6, CHRNA3,
CHRNA5, IREB2,
HHIP
rs1964516,
rs7937,
rs11858836,
rs13141641
41
Genome-wide
association
analysis of body
mass in COPD
U U 3452 FTO rs8050136 42
Variants in FAM13A
are associated
with COPD
U U 9134 FAM13A rs7671167 43
A GWAS in COPD:
identification of 2
major
susceptibility loci
U U 5334 CHRNA3,
NP_001013641.2,
HHIP
rs1051730,
rs8034191,
rs1828591,
rs13118928
44
Abbreviations:U, yes; AFAM, African American; COPD, chronic obstructive pulmonary disease; GWAS, genome-wide association study; SNP, single-nucleotide polymorphism.
The entries of the table have been ordered based on the dates in which the studies were published from the bottom to the top.
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Table V. Polymorphisms associated with idiopathic pulmonary fibrosis and sarcoidosis susceptibility
Study Disease
Sub phenotype Ancestry Control 1 case
(replicates
included) Genes Variants ReferenceSusceptibility Progression European AFAM Hispanic Asian Other
Genetic variants associated with
IPF susceptibility and mortality: a
GWAS
Pulmonary
fibrosis
U U U 3341 MUC5B,
TOLLIP
rs35705950,
rs5743890
47
GWAS identifies multiple
susceptibility loci for pulmonary
fibrosis
U U 8610 DSP, 7q22,
15q14–15,
DPP9
rs2076295,
rs4727443,
rs2034650,
rs12610495
48
A GWAS identifies an association of
a common variant in TERT with
susceptibility to IPF
U U 1711 TERT rs2736100 49
Genome-wide association analysis
reveals 12q13.3-q14.1 as new
risk locus for sarcoidosis
Sarcoidosis U U 9275 OS9 rs1050045 50
A novel sarcoidosis risk locus for
Europeans on chromosome
11q13.1
U U 8878 CCDC88B,
KCNK4,
PRDX5,
PCLB3
rs479777 51
A GWAS reveals evidence of
association with sarcoidosis at
6p12.1
U U 4138 RAB23 rs10484410 52
GWAS identifies ANXA11 as a new
susceptibility locus for
sarcoidosis
U U 4470 ANXA11 rs2789679,
rs7091565
53
Genome-wide association analysis
in sarcoidosis and Crohn’s
disease unravels a common
susceptibility locus on 10p12.2
U U 3582 C10ORF67 rs1398024 54
Abbreviations:U, yes; AFAM, African American; IPF, idiopathic pulmonary fibrosis.
The entries of the table have been ordered based on the dates in which the studies were published from the bottom to the top.
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Table VI. Polymorphisms underlying the normal lung function and susceptibility to miscellaneous pulmonary
diseases
Study Disease/trait
Sub phenotype
Susceptibility Progression Endophenotype Other/description
Genome-wide association
analysis identifies a
susceptibility locus for
pulmonary arterial
hypertension
PVD U
Identification of SPOCK2 as
a susceptibility gene for
BPD
BPD U
Genome-wide association
and large-scale follow up
identifies 16 new loci
influencing lung function
Normal pulmonary function Pulmonary function
Abbreviations:U, yes; AFAM, African American; BPD, bronchopulmonary dysplasia; pulmonary vascular disease.
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2 regions are of biological and clinical interest, namely
10q22.3 and 11q13.1. The former contains ANXA11,
which is essential for cytokinesis and its product is
also detected in the sera of patients with different auto-
immune disorders, as a predisposing gene to sarcoidosis
that has been replicated in patients of non-European
descent, particularly African Americans.53 Other works
had shown the association of the latter with other dis-
eases including alopecia areata, Crohn’s disease,
leprosy, psoriasis, and primary biliary cirrhosis.51 This
region contains CCDC88B, KCNK4, PRDX5, PCLB3
genes with CCDC88B as the most promising putative
sarcoidosis susceptibility gene (Table V).51
Miscellaneous pulmonary diseases. GWAS has suc-
cessfully interrogated various genomic loci in other pul-
monary diseases as well, particularly in bronchopul
monary dysplasia (BPD) and pulmonary arterial hyper-
tension (PAH).
BPD is a chronic form of neonatal respiratory disor-
ders characterized by irreversible airflow obstruction,62with a significant degree of morbidity.63 About one-
third of premature infants in neonatal care units develop
BPD.63 Previous twin studies uncovered that the genetic
factors strongly underpin the development of BPD.64
Despite the clinical importance of BPD, only a limited
number of GWASs have identified putative susceptibil-
ity genetic loci.59,65 Hadchouel et al successfully
identified 2 BPD predisposing polymorphisms,
rs1245560 and rs1049269 of SPOCK2 gene, in which
its expression level is positively correlated with
alveolarization of normal rat lung (Table VI).59 Impor-
tantly, they showed that rs1245560 variant is associated
with BPD susceptibility in both populations of Euro-
pean and African descents.
PAH is a rare lung disorder. The pathologic hallmark
of PAH is the presence of intimal lesions that consist of
eccentric thickening, fibrotic, plexiform, concentric,
and dilation lesions in the vessels of the pulmonary arte-
rial circulation. This translates into persistently high
pulmonary artery pressures, progressive right heart fail-
ure, and a high mortality in untreated patients.66,67
Ancestry Control 1 case
(replicates
included) Genes Variants ReferenceEuropean AFAM Hispanic Asian Other
U 2150 CBLN2 rs2217560, rs9916909 58
U U 603 SPOCK2 rs1245560, rs1049269 59
U 94,612 TNS1, FAM13A, GSTCD-
NPNT, HHIP, HTR4,
ADAM19, AGER, GPR126,
PTCH1, TSHD4, MFAP2,
TGFB2, HDAC4, RARB,
MECOM, SPATA9,
ZKSCAN3, ZNF323, NCR3,
ARMC2, CDC123, C10orf11,
LRP1, CCDC38, MMP15,
CFDP1, KCNE2
rs2571445, rs2869967,
rs2045517, rs7671167,
rs10516526, rs1032296,
rs12504628, rs11100860,
rs1980057,
rs11168048, rs3995090,
rs1985524, rs2277027,
rs11134779, rs2070600,
rs3817928, rs262129,
rs16909859,
rs16909898,
rs12899618, rs8033889,
rs2284746, rs993925,
rs12477314, rs1529672,
rs1344555, rs153916,
rs6903823, rs2857595,
rs2798641, rs7068966,
rs11001819,
rs11172113, rs1036429,
rs12447804, rs2865531,
rs9978142
55
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genotypes with PAH, such as BMPR2 (a member of
transmembrane serine or threonine kinases receptor
families).68 Nevertheless, the finding that mutated
BMPR2 accounts for approximately 80% and 15% of
familial PAH and idiopathic PAH patients prompted
Germain et al to conduct a GWAS to discover novel sus-
ceptibility polymorphisms in these 2 PAH groups.58,68
They particularly controlled for BMPR2 mutation and
found 2 novel SNPs, namely rs2217560 and
rs9916909, which are in complete linkage
disequilibrium. Accordingly, they identified the novel
predisposing gene CBLN2 that resides upstream of
the uncovered SNPs and encodes a protein, which
binds an adhesion molecule in vascular smooth
muscle cells (Table VI).
Systems biology implications of these
polymorphisms. Using expression quantitative trait loci
(eQTL), we identified 2 interesting findings about the
messenger RNAs (mRNAs) in cis and trans associationswith SNPs reported in Tables I–VI (National Center for
Biotechnology Information eQTL Browser; http://ncbi.
nlm.nih.gov/projects/gap/eqtl/index.cgi). There is a
group of 4 asthma risk–associated SNPs in linkage
disequilibrium with one another (Fig 1, A) located on
the chromosome region 17q12 intragenic to 2 host
genes GSDMB and LOC101928947. These 4 SNPs
may be reporting a locus rather than a specific gene,
as they adjust the expression values of either
ORMDL3 or MED24 mRNAs (Fig 1, A). In addition,
both asthma risk SNPs (Table I) rs9272346 (2-kb
upstream of HLA-DQA1) and rs9273349 (2-kb
downstream of HLA-DQB1) are in eQTL associations
with HLA-DQA1 and HLA-DQB1 mRNAs. Given the
transcription direction of these HLA genes, rs9273349
seems to be within a putative enhancer element, which
needs to be experimentally validated. The latter 2
SNPs were also shown in many distinct GWASs that
are associated with immune-related diseases (Fig 1, B;
National Center for Biotechnology Information eQTL
Fig 1. eQTL interaction diagram. The green arrows represent the direction of transcription of the genes. The upper
part of each panel corresponds to the degree of linkage disequilibrium values between the SNPs (blue numbers).
The arrows at the lower part of each panel show the direction of eQTL effects; the expression values of which
genes are adjusted by which SNP (results from eQTL browser). (A) The panel shows that 3 out of 4 well-
replicated asthma polymorphisms (Linkage Disequilibrium . 0.9) reside within GSDMB genes when adjusting
the expression value of the neighboring ORMDL3 gene. (B) The panel represents how 2 other asthma suscepti-
bility polymorphisms adjust the expression values of HLA-DQA1 and HLA-DQB1. rs9273349 is in an intergenic
region, whereas rs9272346 resides 2-kb upstream of the HLA-DQA1. eQTL, expression quantitative trait loci;
SNP, single-nucleotide polymorphism. For interpretation of the references to color in this figure legend, the reader
is referred to the Web version of this article.
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multiple sclerosis, nasal pharyngeal carcinoma,
rheumatoid arthritis, schizophrenia, systemic lupus
erythematous, type I diabetes mellitus). We also used
the Database for Annotation, Visualization and
Integrated Discovery (v6.7; http://david.abcc.ncifcrf.
gov/), to infer the functional relationship among the
gene loci of SNPs reported in Tables I–VI. This
analysis shows that the major biological processes to
which the candidate lung diseases–associated genes
contribute are primarily related to various domains of
immune response, such as cytokine receptor activity
(Supplement Table 1).
NGS technologies and complex pulmonary
diseases. The underlying assumption of GWAS is the
‘‘common disease–common variant hypothesis’’69 in
which small number of alleles contribute to the risk of
development or progression of a given disease and
each allele has small to moderate effect size.
Therefore, previous GWAS thus far has aimed to
discover the association of genetic variants with minorallele frequencies (MAF) .5% and in some cases
MAF .1% within the trait or disease of interest.
However, it is now clear that GWAS discovered
variants explain only a small amount of observed
heritability of the related traits (missing heritability). In
contrast to a common disease–common variant
hypothesis, the ‘‘common disease, rare variant
hypothesis’’ states that genomic loci that confer risk of
disease are cataloged with many rare and independent
risk alleles with modest to high effect size that are
scattered across the population.69 Common disease,
rare variant hypothesis implies the presence of an
extensive degree of genetic heterogeneity in a putative
risk gene or locus and also the lack of linkage
disequilibrium among the variants, thereby debunking
the inherent assumptions of genotyping-based methods
but highlighting the importance of sequencing-based
strategies. Several works have used NGS methods to
identify different lung disease predisposing genetic
variants (Supplement Table 2). Others have used NGS
techniques to profile the metagenome of airways and
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(Supplement Table 2).
Predisposing genetic variants to pulmonary diseases
using DNAseq. DeWan et al70 performed the first
whole exome sequencing (WES) with focus on a
family enriched with asthma. By resequencing the
variants of 3 genes, PDE4DIP, CBLB, and KALRN,
they showed that asthmatic members are heterozygote
opposite to nonasthmatic ones. They did not find the
significant enrichment of selective asthma-related
common variants in genes, ORMDL3, PDE11A,
PDE4D, and RAD50, within affected members. They
were unable to show that the asthmatic members have
significantly higher burden of rare variants. Recently,
Campbell et al71 conducted a whole genome
sequencing on 16 individuals (8 asthmatic) from a
Hutterite population to find novel asthma genetic
variants that have not been uncovered in previous
GWASs. However, none of their discovered variants
met genome-wide significance threshold, specifically
mutations within gene NEDD4L, which contributes to
the ubiquitination of specific proteins for lysosomal
degradation. They were unable to replicate their
findings in other populations of Europeans, African
Americans, and Hispanics. Wain et al72 aimed at
finding putative variants protecting smokers from lung
function decline. They resequenced the exome of 100
smokers with uncompromised lung function, namely
resistant smokers, and 396 individuals from 2
independent control groups. None of their detected
signals survived multiple testing corrections.
However, they reported rs10859974 as the strongest
detected signal in CCDC38 gene, which has been
known to be associated with lung function. Although
this finding is interesting, it demands to be replicated
in additional independent cohorts.
The use of NGS methods has not been limited to
only obstructive pulmonary diseases. Austin et al73
used WES to uncover novel hereditary PAH suscepti-
bility variants in a family in which 4 and 8 members
were affected and unaffected, respectively. By doing
so, they were able to find mutated CAV1 as a new pre-
disposing gene that is a modifier of transforming
growth factor beta (TGF-b) signaling at the plasma
membrane. Interestingly, they noticed that some unaf-
fected members also are carriers of the same mutation,
indicating its incomplete penetrance. Of note, they
controlled for the previously identified heritable
(HPAH) mutated genes, namely ALK1, ENG, or
SMAD9. They replicated their finding in 260 unrelated
patients of Caucasian descent with HPAH and idio-
pathic PAH (IPAH). They also did not detect the
mutated CAV1 in the genotype of 1000 ethnically
matched healthy Caucasian. Ma et al74 also usedWES and studied a family with several affected mem-
bers. They also ruled out the presence of mutations in
previously identified disease predisposing genes. Their
effort gave rise to identifying new candidate predispos-
ing gene, KCNK3 that is a potassium channel subfam-
ily K. Importantly, they replicated their result in 92
unrelated patients with familial PAH and also 230
IPH. Although the nuclear families were the target dis-
covery set of the previous 2 studies, Perez et al75 inter-
rogated the genomes of 12 unrelated IPAH patients
with WES. Consequently, they discovered TopBP1 as
a novel IPAH susceptibility gene.
Recently, some works have also usedWES techniques
to uncover genetic determinants of acute respiratory
distress syndrome (ARDS). Shortt et al76 studied 96 pa-
tients with ARDS (70 Caucasian and 26 African Ameri-
cans) and identified 76 novel ARDS susceptibility SNPs.
They also selectively genotyped 3 of these SNPs,
rs3848719 (ZNF335 gene that contributes in prolifera-
tion of neural progenitor cells and self-renewal),
rs78142040 (ARSD gene that contributes to the develop-
ment of cartilage and is a member of the sulfatase fam-
ily), rs9605146 (in XKR3 gene that is a potential
membrane transporter), in an additional 117 patients
and found the correlation of rs3848719 and rs78142040
with ‘‘Acute Physiology and Chronic Health Evaluation
II’’ (APACHE II) score quartile and 60-day mortality.
Metagenome and association of the microbiome with
pulmonary diseases. Other works have used NGS tech-
niques to examine the association of microbiome diver-
sity in the respiratory tract with susceptibility to lung
disease. In the first effort, Dannemiller et al77 assessed
the association of the various fungal taxa and their
diversity in the house dust with childhood asthma in
low-income Hispanic families. Although positive
association between various taxa with asthma was not
identified, lower fungal diversity, particularly lower
diversity within the genus Cryptococcus, was positively
correlated with asthma susceptibility. Park et al78
studied the potential difference of the microbial
community of upper respiratory tract of 18 asthmatics
and 17 COPD patients compared with 12 healthy
controls. Significant difference between the oropharynx
microbiome of asthmatics and COPD patients was not
discerned, although there was an abundance of
Pseudomonas spp. from Proteobacteria and
Lactobacillus spp. Garzoni et al79 examined the
alteration of the composition of the microbiome in
upper and lower respiratory tracts of 33 individuals with
IIP, sarcoidosis, pneumocystis pneumonia, and healthy
controls to determine disruption in respiratory tract
microbiota and showed altered upper and lower airways
microbiota in 23% patients. Han et al80 used the 454
pyrosequencing method and analyzed the degree of the
Translational Research
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progression of their disease and showed the potential
association of a bacterial signature, members within the
Staphylococcus and Streptococcus genera, with the
patients’ odds of outcome, a correlation that remains
significant after adjusting for genetic effects.DISCUSSION
We have reviewed how GWAS has remarkably
contributed to increasing our knowledge about the
genetic determinants underlying the development and
progression of distinctive pulmonary diseases and their
responses to therapeutics. GWAS has helped re-
searchers to discover the polymorphisms that make in-
dividuals prone to developing various complex lung
diseases such as asthma, COPD, and sarcoidosis.
Despite all the successes that GWASs have achieved
thus far, the variants discovered with GWASs have
yet to explain most of the estimated heritability of
various complex diseases and traits,81,82 and our
understanding about the pathogenesis of pulmonary
diseases has remained incomplete.
Although GWAS is a multiplexed interrogation of the
genome, the downstream biological effect of many
discovered susceptibility variants and the various ways
bywhich they impact on the diseasespathogenesis remain
unclear. It is common that researchersmap the discovered
intergenic variants to the closest neighboring gene.
However, the recent discoveries from ENCyclopedia of
DNA Elements (ENCODE) Project83 have shown that
variants residing in distal regulatory elements might
affect the expression of not necessarily neighboring genes
through various chromatin modification mechanisms.84
Future progress in using new technologies, such as
Hi-C, to explain various epigenomic mechanisms in the
context of lungdiseaseswill provide pulmonary scientists
with a better explanation of the biological impacts of lung
disease genetic variants. Integration of other various tiers
of data, such as protein interaction85 and expression quan-
titative trail loci data,86 is also important to increase the
interpretability of GWAS results. Consequently,
developing more sophisticated computational techniques
and heuristics is necessary.
Much of the GWAS has primarily focused on
measuring the significant association of the variants
individually with disease susceptibility, progression,
or a certain outcome. Nevertheless, it has become
exceedingly clear that the discovered lung disease sus-
ceptibility genetic variants, similar to other complex
diseases, are not capable of explaining all the measured
heritability. Part of this missing heritability resides in
the interaction between distinctive variants. For
example, our work showed that IPF patients mighthave a higher rate of mortality despite inheriting the
protective allele.47 Therefore, devising new innovative
experiments to unravel the epistatic interaction is neces-
sary. On the computational front, development of new
methods to analyze the GWAS data is also needed, spe-
cifically the ones capable of detecting interaction effects
effectively in a reasonable computational time.
Another obvious limitation of GWAS, thus far, is the
lack of work with a focus on admixed populations,
namely African Americans and Hispanics. Most of the
GWASs have primarily targeted patients of European
descent. For example, we found no GWAS for African
American individuals with sarcoidosis in our review.
However, somework has reported the role of various an-
cestries in increment of disease susceptibility and
response to therapeutics.87 For example, Rumpel
et al88 found evidence that asthmatic African Americans
with the higher African ancestry experience higher rate
of severe exacerbation. Another group also reported that
Puerto Ricans have a higher asthma prevalence and its
related morbidities compared with Mexican Ameri-
cans,89,90 despite the fact that both groups are
designated as Hispanics. On the other hand, Choudhry
et al91 found that socioeconomic status (SES) and
ancestry significantly interact with each other among
asthmatic Hispanic individuals. Particularly, they
showed that at the lower spectrum of SES, the European
ancestry correlates more with asthma risk, opposite to
the other end of the SES in which African ancestry is
more associated with the risk of asthma. Therefore, it
is crucial to consider patients’ SES and ancestry in
future GWAS. The under-represented GWASwith focus
on admixed populations could also be partly attributed
to some limitations in the availability of genotyping
technology. Most of the whole-genotyping platforms
incorporate polymorphisms specific for subjects of Eu-
ropean descent, thereby highlighting the urge for
devising more comprehensive genotyping platforms.
Future GWASs should also focus on identifying ge-
netic variants that distinguish various subtypes or clin-
ical manifestations of pulmonary disorders in addition
to asthma. For example, although our review identified
GWAS results for interstitial pulmonary fibrosis, we
found no work related to nonspecific interstitial pneu-
monia or differentiating between different subtypes of
ILD. In addition, our review did not find GWASs iden-
tifying lung disease polymorphisms specific to males or
females (gender-specific polymorphisms). For instance,
although there is a slightly higher prevalence of asthma
attack among women (53.5%),92 GWASs failed to iden-
tify gender-specific asthma polymorphisms when look-
ing for it.11,15,21 As another example, the male gender is
one of the risk factors for predicting the outcome of
IPF,93 yet Fingerlin et al48 did not find any significant
Translational Research
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IPH is 1.7 times more common among women,67
Germain et al58 did not observe any evidence in favor
of existing gender-specific polymorphism.
We also summarized the contribution of various NGS
methods to uncover the role of rare genetic variants in
making individuals prone to various lung diseases. We
further explained how these techniques have been help-
ful for profiling the microbiome of the lung and its inter-
action with pulmonary diseases. NGS methods are
capable of addressing how rare variants confer the dis-
ease risk. Of note, the NGS era indeed heralds the
path to personalizedmedicine. The number of published
works that have used the novel and massively parallel
whole genome sequencing and WES technologies is
still limited. However, a gradual drop in the cost during
the course of the past few years, which is predicted to
continue, will be providing the pulmonary scientist
with a great opportunity to search for the rare variants
that alter the risk to developing various lung diseases
or response to various medications. It is easy to picture
that pulmonologists will add the skill of how to interpret
the results generated from the NGS methods in the near
future to their knowledge repository, subsequently
translating them to routine clinical practice.
In view of all these discoveries and the soon to be
tsunami of personal polymorphisms, the new challenge
is to associate clinically meaningful and actionable
meaning with all these discoveries. As precision health
requires understanding individuals, this may serve as
an additional stimulus to interrogate the genetic makeups
of individuals with Hispanic and African American an-
cestries, as the studies with focus on these populations
are lacking. Other strategies includemore powerful study
designs such as focusing on cases with more extreme and
severe phenotypes, more sophisticated GWAS analysis
technique, and NGS analyzing methods, as well.ACKNOWLEDGMENTS
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